Biogen Idec Appoints Donald Johns to Lead ALS Innovation Hub

Biogen Idec has appointed Donald Johns, M.D., as vice president and head of its ALS Innovation Hub (ALS iHub). The ALS iHub was established as a center of innovation to integrate research and clinical development with cutting-edge new technologies in order to accelerate therapy development for ALS. Dr. Johns’ career spans 30 years in translational research for neurodegenerative diseases. Most recently, he joined Biogen-Idec from Novartis Institutes for Biomedical Research, where he was vice president and global head of Neuroscience Translational Medicine. This ALS iHUB under Dr. Johns’ leadership is a clear demonstration of Biogen-Idec’s commitment to bringing new therapies for ALS into the clinic.

Biogen Idec has appointed Donald Johns, M.D., as vice president and head of its ALS Innovation Hub (ALS iHub). The ALS iHub was established as a center of innovation to integrate research and clinical development with cutting-edge new technologies in order to accelerate therapy development for ALS. Dr. Johns’ career spans 30 years in translational research for neurodegenerative diseases. Most recently, he joined Biogen-Idec from Novartis Institutes for Biomedical Research, where he was vice president and global head of Neuroscience Translational Medicine. This ALS iHUB under Dr. Johns’ leadership is a clear demonstration of Biogen-Idec’s commitment to bringing new therapies for ALS into the clinic.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail